Literature DB >> 30674071

Long-term outcome and recurrence factors after percutaneous cholecystostomy as a definitive treatment for acute cholecystitis.

Jae Keun Park1, Ju-Il Yang1,2, Jin Woo Wi1, Joo Kyung Park1, Kwang Hyuck Lee1, Kyu Taek Lee1, Jong Kyun Lee1.   

Abstract

BACKGROUND AND AIM: Percutaneous cholecystostomy (PC) has been frequently used as an alternative treatment for acute cholecystitis in seriously ill patients unfit for surgery. The aim of this study was to investigate the recurrence rate and risk factors of recurrence.
METHODS: Medical records of 102 patients who were followed up for more than 1 year after PC tube removal among 716 patients who underwent PC for acute cholecystitis treatment were retrospectively analyzed.
RESULTS: The recurrence rate of acute cholecystitis after PC tube removal was 20.6% (21/102), and the mean time to recur was 660 days. Underlying cancer (odds ratio [OR]: 3.369; 95% confidence interval [CI]: 1.006-11.282; P = 0.0489), PC duration shorter than 44 days (OR: 5.596; 95% CI: 1.35-23.201; P = 0.0176), and the presence of common bile duct stone in initial imaging studies (OR: 24.393; 95% CI: 2.696-220.746; P = 0.0045) were positively correlated with recurrence. Tubogram before PC tube removal did not significantly lower the recurrence. However, PC tube clamping for several days significantly lowered the recurrence (OR: 0.108; 95% CI: 0.015-0.794; P = 0.0288). Fifty-nine (57.8%) had acalculous cholecystitis. Calculous cholecystitis was negatively correlated with recurrence (OR: 0.267; 95% CI: 0.074-0.967; P = 0.0444). Receiver operating characteristic curve of the prediction model for recurrence verified its accuracy (area under the curve: 0.8475).
CONCLUSION: We should try to keep PC more than 6 weeks and clamp for 1-2 weeks before removal. For those with the presence of common bile duct stones, calculous cholecystitis, and underlying malignancy, we should keep PC for longer duration and carefully observe symptoms and signs of recurrence.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  acute cholecystitis; percutaneous cholecystostomy; prediction; recurrence

Mesh:

Year:  2019        PMID: 30674071     DOI: 10.1111/jgh.14611

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Management of Symptomatic Gallstone Disease during COVID-19 Lockdown in a High-Resource Setting: Is There a Need for Treatment Alterations?

Authors:  Jens Strohaeker; Julia Sabrow; Can Yurttas; Alfred Königsrainer; Ruth Ladurner; Felix Hoenes
Journal:  Visc Med       Date:  2022-01-27

2.  Correlation of Inpatients Suffering from Acute Acalculous Cholecystitis during ICU Treatment with Acute Physiology and Chronic Health Evaluation II Score, Duration of Ventilator Use, and Time on Total Parenteral Nutrition.

Authors:  Yunfeng Zhang; Kaixian Wang; Yuhui Wang; Yang Liu
Journal:  Comput Math Methods Med       Date:  2022-06-30       Impact factor: 2.809

Review 3.  Image-guided percutaneous cholecystostomy: a comprehensive review.

Authors:  Shayeri Roy Choudhury; Pankaj Gupta; Shikha Garg; Naveen Kalra; Mandeep Kang; Manavjit Singh Sandhu
Journal:  Ir J Med Sci       Date:  2021-05-22       Impact factor: 1.568

Review 4.  Management of Patients With Acute Cholecystitis After Percutaneous Cholecystostomy: From the Acute Stage to Definitive Surgical Treatment.

Authors:  Yu-Liang Hung; Chang-Mu Sung; Chih-Yuan Fu; Chien-Hung Liao; Shang-Yu Wang; Jun-Te Hsu; Ta-Sen Yeh; Chun-Nan Yeh; Yi-Yin Jan
Journal:  Front Surg       Date:  2021-04-15

5.  Percutaneous cholecystostomy as a definitive treatment for moderate and severe acute acalculous cholecystitis: a retrospective observational study.

Authors:  Bai-Qing Chen; Guo-Dong Chen; Feng Xie; Xue Li; Xue Mao; Bao Jia
Journal:  BMC Surg       Date:  2021-12-27       Impact factor: 2.102

6.  What makes acute cholecystitis recur after removing the percutaneous cholecystostomy tube?

Authors:  Jun Heo; Min Kyu Jung; Chang Min Cho; Sang Yub Lee; Hun Kyu Ryeom; Jae Min Chun; Young Seok Han; Hyung Jun Kwon
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.